MedTrace Logo

A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients

NCT02765815 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-08-09

No results posted yet for this study

Summary

This is a prospective, single-center, single-blinded, randomized, case-control study. The study is conducted by a single investigator at an orthopedic surgery institute, with a minimum 6 week post operative follow-up period of TKA patients who receive Exparel compared with the surgeon's standard method (detailed below) for pain management intraoperatively.

Conditions

  • Osteoarthritis, Knee
  • Arthroplasty, Replacement, Knee

Interventions

DRUG

Liposomal bupivacaine, 266mg

DRUG

Bupivacaine 0.5 % with Epinephrine

DRUG

Ketorolac 30mg

DRUG

Morphine 10mg

DRUG

Bupivacaine 0.25% with Epinephrine

Sponsors & Collaborators

  • Holy Cross Hospital, Florida

    lead OTHER

Principal Investigators

  • Martin Roche, MD · Holy Cross Orthopedic Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02765815 on ClinicalTrials.gov